CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Potential Therapeutic Targeting of lncRNAs in Cholesterol Homeostasis

Ye, Wen-Chu, Huang, Shi-Feng, Hou, Lian-Jie, Long, Hai-Jiao, Yin, Kai, Hu, Ching Yuan, Zhao, Guo-Jun·2021·Frontiers in Cardiovascular Medicine
DOI 10.3389/fcvm.2021.688546PMC PMC8224755
Open this paper in CoChat — free account

Abstract

Maintaining cholesterol homeostasis is essential for normal cellular and systemic functions. Long non-coding RNAs (lncRNAs) represent a mechanism to fine-tune numerous biological processes by controlling gene expression. LncRNAs have emerged as important regulators in cholesterol homeostasis. Dysregulation of lncRNAs expression is associated with lipid-related diseases, suggesting that manipulating the lncRNAs expression could be a promising therapeutic approach to ameliorate liver disease progression and cardiovascular disease (CVD). However, given the high-abundant lncRNAs and the poor genetic conservation between species, much work is required to elucidate the specific role of lncRNAs in regulating cholesterol homeostasis. In this review, we highlighted the latest advances in the pivotal role and mechanism of lncRNAs in regulating cholesterol homeostasis. These findings provide novel insights into the underlying mechanisms of lncRNAs in lipid-related diseases and may offer potential therapeutic targets for treating lipid-related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcvm.2021.688546

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several DEGs previously associated with lipid metabolism were identified, including MIAT, COMT, NRP1, VEGFB, GRAMD1B, DSEL, and FUT9 associated with glycan structure.

    “We identified several DEGs that have been previously associated with lipid metabolism, including MIAT, COMT, NRP1, VEGFB, GRAMD1B, DSEL56–62, as well as FUT9 associated with glycan structure63,64 (Fig. 4a).”

    From GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau (2025) · cites this paper as [57]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 145

  1. Goldstein, 1990, Regulation of the mevalonate pathway, Nature., 343, 425, 10.1038/343425a0 · DOI · Paper page
  2. Cruz, 2013, The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics, Front Pharmacol., 4, 119, 10.3389/fphar.2013.00119 · DOI
  3. Luo, 2020, Mechanisms and regulation of cholesterol homeostasis, Nat Rev Mol Cell Biol., 21, 225, 10.1038/s41580-019-0190-7 · DOI · Paper page
  4. Benito-Vicente, 2018, Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease, Int J Mol Sci., 19, 3426, 10.3390/ijms19113426 · DOI
  5. Defesche, 2017, Familial hypercholesterolaemia, Nat Rev Dis Primers., 3, 17093, 10.1038/nrdp.2017.93 · DOI · Paper page
  6. Singh, 2018, Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins, Semin Cell Dev Biol., 81, 129, 10.1016/j.semcdb.2017.11.026 · DOI
  7. Liu, 2017, Emerging roles and mechanisms of long noncoding RNAs in atherosclerosis, Int J Cardiol., 228, 570, 10.1016/j.ijcard.2016.11.182 · DOI
  8. Ou, 2020, Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter, EBioMedicine., 55, 102694, 10.1016/j.ebiom.2020.102694 · DOI
  9. Han, 2019, PTPRE-AS1LncRNA modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE, Sci Adv., 5, eaax9230, 10.1126/sciadv.aax9230 · DOI
  10. Zhao, 2017, Post-transcriptional gene regulation by mRNA modifications, Nat Rev Mol Cell Biol., 18, 31, 10.1038/nrm.2016.132 · DOI
  11. Dai, 2018, N6-methyladenosine links RNA metabolism to cancer progression, Cell Death Dis., 9, 124, 10.1038/s41419-017-0129-x · DOI
  12. Zhao, 2020, Epitranscriptomics in liver disease: Basic concepts and therapeutic potential, J Hepatol., 73, 664, 10.1016/j.jhep.2020.04.009 · DOI
  13. Jian, 2020, METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications, Theranostics., 10, 8939, 10.7150/thno.45178 · DOI
  14. Fang, 2021, EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma, Nat Commun., 12, 177, 10.1038/s41467-020-20379-7 · DOI
  15. Park, 2020, Mono-(2-Ethylhexyl)phthalate regulates cholesterol efflux via MicroRNAs regulated mA RNA methylation, Chem Res Toxicol., 33, 461, 10.1021/acs.chemrestox.9b00367 · DOI
  16. Wu, 2020, Resveratrol attenuates high-fat diet induced hepatic lipid homeostasis disorder and decreases mA RNA methylation, Front Pharmacol., 11, 568006, 10.3389/fphar.2020.568006 · DOI
  17. Qin, 2020, Role of m6A RNA methylation in cardiovascular disease (Review), Int J Mol Med., 46, 1958, 10.3892/ijmm.2020.4746 · DOI
  18. Poller, 2018, Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives, Eur Heart J., 39, 2704, 10.1093/eurheartj/ehx165 · DOI
  19. Zhao, 2018, Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis, Nat Commun., 9, 2986, 10.1038/s41467-018-05383-2 · DOI
  20. Li, 2015, A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice, Cell Metab., 21, 455, 10.1016/j.cmet.2015.02.004 · DOI
  21. Dong, 2021, The long noncoding RNA RP11-728F11.4 promotes atherosclerosis, Arterioscl Thromb Vasc Biol., 41, 1191, 10.1161/ATVBAHA.120.315114 · DOI
  22. Simion, 2020, A macrophage-specific lncRNA regulates apoptosis and atherosclerosis by tethering HuR in the nucleus, Nat Commun., 11, 6135, 10.1038/s41467-020-19664-2 · DOI
  23. Yang, 2018, N6-Methyladenosine modification of lincRNA 1281 is critically required for mESC differentiation potential, Nucl Acids Res., 46, 3906, 10.1093/nar/gky130 · DOI
  24. Lan, 2019, KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3, Mol Cancer., 18, 186, 10.1186/s12943-019-1106-z · DOI
  25. Jin, 2019, mA mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis, J Hematol Oncol., 12, 135, 10.1186/s13045-019-0830-6 · DOI
  26. Li, 2019, LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/β-catenin signaling pathway, Lipids Health Dis., 18, 62, 10.1186/s12944-019-1006-7 · DOI
  27. Durbin, 2002, Advances towards understanding heart valve response to injury, Cardiovasc Pathol., 11, 69, 10.1016/S1054-8807(01)00109-0 · DOI
  28. Zhang, 2020, Long noncoding RNA XIST/miR-17/PTEN axis modulates the proliferation and apoptosis of vascular smooth muscle cells to affect stanford Type A aortic dissection, J Cardiovasc Pharmacol., 76, 53, 10.1097/FJC.0000000000000835 · DOI
  29. Yan, 2016, Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability, Sci Rep., 6, 22640, 10.1038/srep22640 · DOI
  30. Cremer, 2019, Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation, Circulation., 139, 1320, 10.1161/CIRCULATIONAHA.117.029015 · DOI
  31. Gao, 2021, LncRNA XIST regulates atherosclerosis progression in ox-LDL-induced HUVECs, Open Med., 16, 117, 10.1515/med-2021-0200 · DOI
  32. Li, 2019, Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression, Aging., 11, 1695, 10.18632/aging.101863 · DOI
  33. Hennessy, 2019, The long noncoding RNA CHROME regulates cholesterol homeostasis in primate, Nat Metab., 1, 98, 10.1016/j.atherosclerosis.2019.06.890 · DOI
  34. Cai, 2019, LncRNA ENST00000602558.1 regulates ABCG1 expression and cholesterol efflux from vascular smooth muscle cells through a p65-dependent pathway, Atherosclerosis., 285, 31, 10.1016/j.atherosclerosis.2019.04.204 · DOI
  35. Shen, 2019, Silencing of GAS5 represses the malignant progression of atherosclerosis through upregulation of miR-135a, Biomed Pharmacother., 118, 109302, 10.1016/j.biopha.2019.109302 · DOI
  36. Huang, 2019, LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6, Metab Clin Experi., 94, 1, 10.1016/j.metabol.2019.01.018 · DOI
  37. Wang, 2020, Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes, J Cell Mol Med., 24, 1399, 10.1111/jcmm.14818 · DOI
  38. Liu, 2020, Long non-coding RNA MALAT1 regulates cholesterol accumulation in ox-LDL-induced macrophages via the microRNA-17-5p/ABCA1 axis, Mol Med Rep., 21, 1761, 10.3892/mmr.2020.10987 · DOI
  39. Huang, 2016, Long noncoding RNA HOXC-AS1 suppresses Ox-LDL-induced cholesterol accumulation through promoting HOXC6 expression in THP-1 macrophages, DNA Cell Biol., 35, 722, 10.1089/dna.2016.3422 · DOI
  40. Pang, 2018, HOTAIR alleviates ox-LDL-induced inflammatory response in Raw264.7 cells via inhibiting NF-κB pathway, Eur Rev Med Pharmacol Sci., 22, 6991, 10.26355/eurrev_201810_16170 · DOI
  41. Chen, 2019, LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease, Life Sci., 235, 116829, 10.1016/j.lfs.2019.116829 · DOI
  42. Lan, 2019, Long noncoding RNA lnc-HC regulates PPARγ-mediated hepatic lipid metabolism through miR-130b-3p, Mol Therapy Nucleic Acids., 18, 954, 10.1016/j.omtn.2019.10.018 · DOI
  43. Li, 2020, A novel plasma lncRNA ENST00000416361 is upregulated in coronary artery disease and is related to inflammation and lipid metabolism, Mol Med Rep., 21, 2375, 10.3892/mmr.2020.11067 · DOI
  44. Sallam, 2016, Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis, Nature., 534, 124, 10.1038/nature17674 · DOI · Paper page
  45. Zhang, 2018, The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma, Biochem Biophys Res Commun., 507, 337, 10.1016/j.bbrc.2018.11.036 · DOI
  46. Mohamadi, 2019, Deregulation of long noncoding RNA SNHG17 and TTC28-AS1 is associated with type 2 diabetes mellitus, Scand J Clin Lab Investig., 79, 519, 10.1080/00365513.2019.1664760 · DOI
  47. Wu, 2019, Association of N-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts, Cell Death Dis., 10, 909, 10.1038/s41419-019-2152-6 · DOI
  48. Hu, 2015, RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction, Arterioscl Thromb Vasc Biol., 35, 87, 10.1161/ATVBAHA.114.304296 · DOI
  49. Zuo, 2020, M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma, J Hematol Oncol., 13, 5, 10.1186/s13045-019-0839-x · DOI
  50. Zeng, 2018, Long noncoding RNAs: advances in lipid metabolism, Adv Clin Chem., 87, 1, 10.1016/bs.acc.2018.07.001 · DOI
  51. Chen, 2016, Progress and prospects of long noncoding RNAs in lipid homeostasis, Mol Metab, 5, 164, 10.1016/j.molmet.2015.12.003 · DOI
  52. Ye, 2019, LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation, Cell Death Dis., 10, 138, 10.1038/s41419-019-1409-4 · DOI
  53. Sun, 2019, Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway, Drug Deliv., 26, 641, 10.1080/10717544.2019.1628116 · DOI
  54. Li, 2020, ALKBH1 promotes lung cancer by regulating m6A RNA demethylation, Biochem Pharmacol., 14, 114284, 10.1016/j.bcp.2020.114284 · DOI
  55. Pan, 2017, LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway, Eur Rev Med Pharmacol Sci, 21, 322
  56. Huang, 2019, Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5, Front Neurol., 10, 32, 10.3389/fneur.2019.00032 · DOI
  57. Yang, 2019, Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1 expression in ApoE knockout mice, Aging., 11, 10016, 10.18632/aging.102388 · DOI
  58. Liu, 2019, LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease, Biosci Rep, 39, BSR20181722, 10.1042/BSR20181722 · DOI
  59. Wang, 2018, Sonodynamic therapy-induced foam cells apoptosis activates the phagocytic PPARγ-LXRα-ABCA1/ABCG1 pathway and promotes cholesterol efflux in advanced plaque, Theranostics., 8, 4969, 10.7150/thno.26193 · DOI
  60. Chen, 2016, Global transcriptomic study of atherosclerosis development in rats, Gene., 592, 43, 10.1016/j.gene.2016.07.023 · DOI
  61. Meng, 2020, Knockdown of GAS5 inhibits atherosclerosis progression via reducing EZH2-mediated ABCA1 transcription in ApoE mice, Mol Ther Nucleic Acids., 19, 84, 10.1016/j.omtn.2019.10.034 · DOI
  62. Liu, 2019, Baicalin inhibits proliferation and promotes apoptosis of vascular smooth muscle cells by regulating the MEG3/p53 pathway following treatment with ox-LDL, Int J Mol Med., 43, 901, 10.3892/ijmm.2018.4009 · DOI
  63. Yang, 2018, Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U, Cancer Lett., 413, 23, 10.1016/j.canlet.2017.10.028 · DOI
  64. Zhu, 2019, lncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression, Int J Mol Med., 43, 345, 10.3892/ijmm.2018.3975 · DOI
  65. Ha, 2019, Genetics-driven discovery of novel regulators of lipid metabolism, Curr Opin Lipidol., 30, 157, 10.1097/MOL.0000000000000605 · DOI
  66. Zhao, 2017, Long non-coding RNA in liver metabolism and disease: current status, Liver Res., 1, 163, 10.1016/j.livres.2017.09.001 · DOI
  67. Ceroi, 2016, LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis, Blood., 128, 2694, 10.1182/blood-2016-06-724807 · DOI
  68. Nakaya, 2007, Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma, J Atheroscl Thromb., 14, 133, 10.5551/jat.14.133 · DOI
  69. Bayoglu, 2016, Polymorphisms in the long non-coding RNA CDKN2B-AS1 may contribute to higher systolic blood pressure levels in hypertensive patients, Clin Biochem., 49, 821, 10.1016/j.clinbiochem.2016.02.012 · DOI
  70. Haag, 2018, Targeting STING with covalent small-molecule inhibitors, Nature., 559, 269, 10.1038/s41586-018-0287-8 · DOI · Paper page
  71. Huang, 2018, LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis, Cancer Lett., 437, 56, 10.1016/j.canlet.2018.08.024 · DOI
  72. Restrepo, 2018, Local genetic ancestry in CDKN2B-AS1 is associated with primary open-angle glaucoma in an African American cohort extracted from de-identified electronic health records, BMC Med Genom., 11, 70, 10.1186/s12920-018-0392-4 · DOI
  73. Hubberten, 2019, Linear isoforms of the long noncoding RNA CDKN2B-AS1 regulate the c-myc-enhancer binding factor RBMS1, Eur J Human Genet: EJHG., 27, 80, 10.1038/s41431-018-0210-7 · DOI
  74. Li, 2019, Regulation of cholesterol homeostasis by a novel long non-coding RNA LASER, Sci Rep., 9, 7693, 10.1038/s41598-019-44195-2 · DOI
  75. Seidah, 2014, PCSK9: a key modulator of cardiovascular health, Circul Res., 114, 1022, 10.1161/CIRCRESAHA.114.301621 · DOI
  76. Gao, 2019, MiR-127 attenuates adipogenesis by targeting MAPK4 and HOXC6 in porcine adipocytes, J Cell Physiol., 234, 21838, 10.1002/jcp.28660 · DOI
  77. Huang, 2018, Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway, Life Sci., 203, 48, 10.1016/j.lfs.2018.04.028 · DOI
  78. Cirera-Salinas, 2012, Mir-33 regulates cell proliferation and cell cycle progression, Cell Cycle., 11, 922, 10.4161/cc.11.5.19421 · DOI
  79. Zhao, 2017, Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease, Nat Genet., 49, 1450, 10.1038/ng.3943 · DOI
  80. Klarin, 2017, Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease, Nat Genet., 49, 1392, 10.1038/ng.3914 · DOI
  81. Li, 2018, Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease, Atherosclerosis., 275, 359, 10.1016/j.atherosclerosis.2018.06.866 · DOI
  82. Ma, 2018, Propofol suppresses proinflammatory cytokine production by increasing ABCA1 expression via mediation by the long noncoding RNA LOC286367, Media Inflamm., 2018, 8907143, 10.1155/2018/8907143 · DOI
  83. Joyce, 2002, The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, Proc Natl Acad Sci USA., 99, 407, 10.1073/pnas.012587699 · DOI
  84. Gao, 2019, CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-catenin/TCF21 pathway, J Lipid Res., 60, 2020, 10.1194/jlr.RA119000100 · DOI
  85. Correia de Sousa, 2019, Deciphering miRNAs' action through miRNA editing, Int J Mol Sci, 20, 24, 10.3390/ijms20246249 · DOI
  86. Zhang, 2017, The long noncoding RNA Malat1: Its physiological and pathophysiological functions, RNA Biol., 14, 1705, 10.1080/15476286.2017.1358347 · DOI
  87. Bhan, 2017, Long noncoding RNA and cancer: a new paradigm, Cancer Res., 77, 3965, 10.1158/0008-5472.CAN-16-2634 · DOI
  88. Lodde, 2020, Long noncoding RNAs and circular RNAs in autoimmune diseases, Biomolecules, 10, 1044, 10.3390/biom10071044 · DOI
  89. Wu, 2019, Long noncoding RNA (lncRNA): a target in neuropathic pain, Exp Opin Therap Targets., 23, 15, 10.1080/14728222.2019.1550075 · DOI
  90. Uchida, 2015, Long noncoding RNAs in cardiovascular diseases, Circul Res., 116, 737, 10.1161/CIRCRESAHA.116.302521 · DOI
  91. Zhang, 2012, Long non-coding RNA expression profiles predict clinical phenotypes in glioma, Neurobiol Dis., 48, 1, 10.1016/j.nbd.2012.06.004 · DOI
  92. Yu, 2015, Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas, J Thorac Oncol., 10, 645, 10.1097/JTO.0000000000000470 · DOI
  93. Qin, 2021, A novel long non-coding RNA lnc030 maintains breast cancer stem cell stemness by stabilizing SQLE mRNA and increasing cholesterol synthesis, Adv Sci., 8, 2002232, 10.1002/advs.202002232 · DOI
  94. Wang, 2021, lncRNA PVT1 promotes the migration of gastric cancer by functioning as ceRNA of miR-30a and regulating Snail, J Cell Physiol., 236, 536, 10.1002/jcp.29881 · DOI
  95. Yuan, 2020, LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5, Oncogene., 39, 6664, 10.1038/s41388-020-01460-3 · DOI
  96. Lemos, 2019, PCA3The long non-coding RNA: an update of its functions and clinical applications as a biomarker in prostate cancer, Oncotarget., 10, 6589, 10.18632/oncotarget.27284 · DOI
  97. Yörüker, 2018, Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer, Biomed Rep., 9, 181, 10.3892/br.2018.1116 · DOI
  98. Liu, 2019, Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma, Cancer Lett., 454, 158, 10.1016/j.canlet.2019.04.008 · DOI
  99. Xu, 2020, Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer, Int J Cancer., 146, 2901, 10.1002/ijc.32747 · DOI
  100. Guo, 2020, Circulating exosomal gastric cancer-associated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: a multiphase study, JAMA Surg., 155, 572, 10.1001/jamasurg.2020.1133 · DOI
  101. Cantile, 2020, HOTAIRLong non-coding RNA in breast cancer therapy, Cancers, 12, 508, 10.3390/cancers12051197 · DOI
  102. Kim, 2020, HOTAIRGenetic variants of associated with colorectal cancer susceptibility and mortality, Front Oncol., 10, 72, 10.3389/fonc.2020.00072 · DOI
  103. Zheng, 2020, Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer, J Cell Mol Med., 24, 5578, 10.1111/jcmm.15214 · DOI
  104. Zhang, 2020, HOTAIR contributes to the carcinogenesis of gastric cancer via modulating cellular and exosomal miRNAs level, Cell Death Dis., 11, 780, 10.1038/s41419-020-02946-4 · DOI
  105. Liu, 2020, Long non-coding RNA HOTAIR promotes cell viability, migration and invasion in thyroid cancer cells by sponging miR-17-5p, Neoplasma., 67, 229, 10.4149/neo_2019_190310N208 · DOI
  106. Lu, 2020, The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome, Med Res Rev., 41, 1751, 10.1002/med.21775 · DOI
  107. Cai, 2016, Circulating 'lncRNA OTTHUMT00000387022' from monocytes as a novel biomarker for coronary artery disease, Cardiovas Res., 112, 714, 10.1093/cvr/cvw022 · DOI
  108. Yang, 2015, Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease, Clin Sci., 129, 675, 10.1042/CS20150121 · DOI
  109. Kumarswamy, 2014, Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure, Circul Res., 114, 1569, 10.1161/CIRCRESAHA.114.303915 · DOI
  110. Wang, 2020, Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction, Int J Cardiol., 302, 15, 10.1016/j.ijcard.2019.12.058 · DOI
  111. Vausort, 2014, Long noncoding RNAs in patients with acute myocardial infarction, Circul Res., 115, 668, 10.1161/CIRCRESAHA.115.303836 · DOI
  112. Zheng, 2020, Circulating exosomal long non-coding RNAs in patients with acute myocardial infarction, J Cell Mol Med., 24, 9388, 10.1111/jcmm.15589 · DOI
  113. Xiu, 2019, LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription, Mol Cancer., 18, 187, 10.1186/s12943-019-1115-y · DOI
  114. Li, 2020, Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas, Cell Death Dis., 11, 672, 10.1038/s41419-020-02820-3 · DOI
  115. Arun, 2016, Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss, Genes Dev., 30, 34, 10.1101/gad.270959.115 · DOI
  116. Gutschner, 2013, The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells, Cancer Res., 73, 1180, 10.1158/0008-5472.CAN-12-2850 · DOI
  117. Gao, 2018, Long non-coding RNAs associated with metabolic traits in human white adipose tissue, EBioMedicine., 30, 248, 10.1016/j.ebiom.2018.03.010 · DOI
  118. Shi, 2019, Stabilization of lncRNA GAS5 by a small molecule and its implications in diabetic adipocytes, Cell Chem Bio., 26, 319, 10.1016/j.chembiol.2018.11.012 · DOI
  119. Wu, 2017, Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma, Neuro-oncology., 19, 1195, 10.1093/neuonc/nox017 · DOI
  120. Mercatelli, 2020, Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC, Cancer Lett., 469, 111, 10.1016/j.canlet.2019.10.026 · DOI
  121. Li, 2019, A compound AC1Q3QWB selectively disrupts HOTAIR-mediated recruitment of PRC2 and enhances cancer therapy of DZNep, Theranostics., 9, 4608, 10.7150/thno.35188 · DOI
  122. Cho, 2018, Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element, Cell., 173, 1398, 10.1016/j.cell.2018.03.068 · DOI · Paper page
  123. Zhen, 2017, Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer, Oncotarget., 8, 9634, 10.18632/oncotarget.14176 · DOI
  124. Beaver, 2017, Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer, J Nutrit Biochem., 42, 72, 10.1016/j.jnutbio.2017.01.001 · DOI
  125. Liu, 2018, Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer, Cell Death Dis., 9, 168, 10.1038/s41419-017-0246-6 · DOI
  126. Leisegang, 2017, Long noncoding RNA MANTIS facilitates endothelial angiogenic function, Circulation., 136, 65, 10.1161/CIRCULATIONAHA.116.026991 · DOI
  127. Bernardo, 2015, miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart, Future Med Chem., 7, 1771, 10.4155/fmc.15.107 · DOI
  128. Gong, 2019, Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis, ACS Appl Mater Interfaces., 11, 37, 10.1021/acsami.8b18288 · DOI
  129. Amodio, 2018, MALAT1 a druggable long non-coding RNA for targeted anti-cancer approaches, J Hematol Oncol., 11, 63, 10.1186/s13045-018-0606-4 · DOI
  130. Lee, 2020, Antisense-mediated transcript knockdown triggers premature transcription termination, Mol Cell., 77, 1044, 10.1016/j.molcel.2019.12.011 · DOI
  131. Wan, 2016, The medicinal chemistry of therapeutic oligonucleotides, J Med Chem., 59, 9645, 10.1021/acs.jmedchem.6b00551 · DOI
  132. Stein, 2017, FDA-Approved oligonucleotide therapies in 2017, Mol Ther., 25, 1069, 10.1016/j.ymthe.2017.03.023 · DOI
  133. Dhuri, 2020, Antisense oligonucleotides. An emerging area in drug discovery and development, J Clin Med, 9, 2004, 10.3390/jcm9062004 · DOI
  134. Chandra Gupta, 2017, Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets, Int J Cancer., 140, 1955, 10.1002/ijc.30546 · DOI
  135. Yang, 2019, Role of long non-coding RNAs in lymphoma: a systematic review and clinical perspectives, Crit Rev Oncol Hematol., 141, 13, 10.1016/j.critrevonc.2019.05.007 · DOI
  136. Uroda, 2019, Conserved pseudoknots in lncRNA MEG3 are essential for stimulation of the p53 pathway, Mol Cell., 75, 982, 10.1016/j.molcel.2019.07.025 · DOI
  137. Somarowthu, 2015, HOTAIR forms an intricate and modular secondary structure, Mol Cell., 58, 353, 10.1016/j.molcel.2015.03.006 · DOI
  138. Yuan, 2019, LncRNA H19 knockdown in human amniotic mesenchymal stem cells suppresses angiogenesis by associating with EZH2 and activating vasohibin-1, Stem Cells Dev., 28, 781, 10.1089/scd.2019.0014 · DOI
  139. Balas, 2021, Establishing RNA-RNA interactions remodels lncRNA structure and promotes PRC2 activity, Sci Adv, 7, eabc9191, 10.1126/sciadv.abc9191 · DOI
  140. Yap, 2010, Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a, Mol Cell., 38, 662, 10.1016/j.molcel.2010.03.021 · DOI · Paper page
  141. van der Oost Westra, 2014, Unravelling the structural and mechanistic basis of CRISPR-Cas systems, Nat Rev Microbiol., 12, 479, 10.1038/nrmicro3279 · DOI
  142. Qi, 2013, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression, Cell., 152, 1173, 10.1016/j.cell.2013.02.022 · DOI · Paper page
  143. Esposito, 2019, Hacking the cancer genome. Profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening, Cancer Cell., 35, 545, 10.1016/j.ccell.2019.01.019 · DOI
  144. Wilusz, 2009, Long noncoding RNAs: functional surprises from the RNA world, Genes Dev., 23, 1494, 10.1101/gad.1800909 · DOI
  145. Sánchez, 2013, Long non-coding RNAs: challenges for diagnosis and therapies, Nucl Acid Therap., 23, 15, 10.1089/nat.2012.0414 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ye, W.-C., Huang, S.-F., Hou, L.-J., Long, H.-J., Yin, K., Hu, C. Y., & Zhao, G.-J.
Venue
Frontiers in Cardiovascular Medicine
Publisher
Frontiers Media SA
Published
2021-06-10
Volume
8
ISSN
2297-055X
DOI
10.3389/fcvm.2021.688546
PMC
PMC8224755
Cited by
19
References
3
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review